Plastic Products · Founded 1976 · www.cosmofilms.com · BSE 508814 · NSE COSMOFIRST · ISIN INE757A01017
No Notes Added Yet
Business
Cosmo First Ltd. (formerly Cosmo Films Ltd.) is a global manufacturer of Bi-axially Oriented Polypropylene (BOPP) films and Cast Polypropylene (CPP) films. These films serve various applications, including flexible packaging, labeling, lamination, and industrial uses across food, personal care, pharmaceutical, and other sectors. The company has a significant focus on specialty films that offer enhanced properties like barrier, thermal lamination, and synthetic paper substitutes. In recent years, Cosmo First has diversified its business beyond films into new ventures such as an omnichannel pet care platform (Zigly), and specialty chemicals (adhesives, coatings, masterbatches). The core business model involves manufacturing and supplying these films and related products directly to converters, brand owners, and industrial users, generating revenue from their sales.
Revenue Mix
The company's primary business segment remains Films, encompassing BOPP, CPP, and a growing portfolio of specialty films. This segment historically accounts for the vast majority of its revenue (typically over 90-95%).
In recent years, Cosmo First has strategically diversified into "New Businesses," which include:
Pet Care (Zigly): An omnichannel platform offering pet products, veterinary services, and grooming. This segment is in its growth phase and currently contributes a small but increasing portion of the total revenue.
Specialty Chemicals: Manufacturing adhesives, coatings, and masterbatches for various industries. This segment is also growing and contributing to the overall revenue, aiming for higher-margin products.
Specific percentage contributions for these new segments are not consistently detailed as significant revenue generators compared to the Films business in latest public disclosures but represent strategic diversification for future growth.
Industry
Cosmo First operates within the highly competitive global plastic film manufacturing industry, particularly in flexible packaging. The industry for commodity BOPP and CPP films is often characterized by significant competition and sensitivity to raw material prices. However, the market for specialty and value-added films offers opportunities for differentiation and higher margins. Cosmo First is one of the leading manufacturers of BOPP films globally and a significant player in India. It has strategically positioned itself by investing heavily in R&D to develop a wide range of specialty films, which allows it to move up the value chain, reduce reliance on commodity films, and cater to evolving customer demands for performance and sustainability.
MOAT
Scale and Cost Efficiency: As a large-scale manufacturer in India, Cosmo First benefits from economies of scale in production, which can lead to cost advantages in commodity film segments.
R&D and Product Innovation: A strong focus on research and development, particularly in specialty films (e.g., barrier films, synthetic paper, direct thermal printable films), provides a competitive edge by offering unique and high-performance products that command better margins and create switching costs for customers.
Established Customer Relationships & Global Presence: Long-standing relationships with a diverse global customer base (converters, brand owners) built on product quality and service.
Brand Reputation: A strong brand reputation in the B2B flexible packaging and labeling industry for quality and reliability.
Growth Drivers
Growing Flexible Packaging Demand: Increasing consumption of packaged food, personal care, and pharmaceutical products, especially in emerging markets, fuels demand for flexible packaging films.
E-commerce Growth: The rapid expansion of e-commerce necessitates a significant amount of protective and functional packaging.
Shift to Specialty Films: Increasing adoption of high-performance and specialty films due to demand for enhanced product protection, extended shelf life, and sustainable packaging solutions.
Capacity Expansion & New Product Development: Continuous investment in expanding manufacturing capacities and launching innovative film products.
Diversification into New Businesses: Growth and scaling of the pet care (Zigly) and specialty chemicals businesses can open new revenue streams and reduce dependence on the films segment.
Risks
Raw Material Price Volatility: Key raw materials like polypropylene resin are crude oil derivatives, making the company susceptible to fluctuations in crude oil prices, which can impact profitability.
Intense Competition & Overcapacity: The commodity film segment faces intense competition and potential overcapacity, leading to pricing pressure and margin erosion.
Environmental Regulations: Increasing global scrutiny and regulations on single-use plastics and plastic waste could impact demand or necessitate significant investments in sustainable alternatives.
Currency Fluctuations: As an exporter and importer of raw materials, the company is exposed to foreign exchange rate volatility.
Execution Risk in Diversification: The success of new ventures like Zigly and specialty chemicals depends on effective execution, market acceptance, and significant investment, which carry inherent risks.
Global Economic Slowdown: A slowdown in global economic growth can reduce industrial demand for films and packaged goods.
Management & Ownership
Cosmo First Ltd. is promoted by the Jain family. Mr. Ashok Jaipuria is the Chairman and Managing Director, having founded the company and provided long-term leadership. The management team also includes professionals leading various business units. The promoter group holds a significant stake in the company (typically in the range of 45-50%), aligning their interests with those of other shareholders. The company has transitioned from a film-focused entity to a diversified group under its current leadership, indicating a strategic shift towards broader opportunities.
Outlook
Cosmo First Ltd. presents a mixed but generally positive outlook. The core film business benefits from a growing global demand for flexible packaging and a strategic pivot towards higher-margin specialty films, which offer better insulation from commodity price volatility and competition. Investments in R&D and capacity expansion for these value-added products are key strengths. The diversification into pet care and specialty chemicals, while currently smaller in revenue contribution, provides new avenues for growth and reduces long-term reliance on the cyclical film business, potentially enhancing enterprise value. However, the company remains exposed to significant risks from volatile raw material prices, intense competition in commodity film segments, and evolving environmental regulations regarding plastics. The successful execution and scaling of its new ventures will be crucial for realizing its long-term growth ambitions.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 625 | 641 | 690 | 759 | 701 | 746 | 800 | 919 | 899 | 1021 |
| Other Income | 14 | 23 | 17 | 20 | 23 | 15 | 24 | 25 | 35 | 17 |
| Total Income | 639 | 665 | 706 | 779 | 724 | 761 | 824 | 944 | 934 | 1038 |
| Total Expenditure | 582 | 597 | 622 | 672 | 638 | 676 | 708 | 816 | 831 | 900 |
| Operating Profit | 56 | 67 | 84 | 107 | 86 | 85 | 116 | 128 | 103 | 138 |
| Interest | 23 | 26 | 23 | 25 | 25 | 27 | 32 | 37 | 37 | 36 |
| Depreciation | 23 | 24 | 24 | 24 | 25 | 26 | 30 | 34 | 35 | 37 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7 |
| Profit Before Tax | 10 | 18 | 37 | 57 | 36 | 33 | 54 | 57 | 31 | 58 |
| Provision for Tax | -1 | 2 | 6 | 11 | 7 | 5 | 12 | 11 | 2 | 21 |
| Profit After Tax | 11 | 15 | 31 | 46 | 30 | 27 | 43 | 47 | 30 | 37 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 11 | 15 | 31 | 46 | 30 | 27 | 43 | 47 | 30 | 37 |
| Adjusted Earnings Per Share | 4.3 | 5.9 | 11.8 | 17.4 | 11.3 | 10.3 | 16.3 | 17.8 | 11.2 | 14.1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1647 | 1621 | 1587 | 1847 | 2157 | 2204 | 2285 | 3038 | 3065 | 2587 | 2895 | 3639 |
| Other Income | 5 | 6 | 15 | 35 | 20 | 19 | 38 | 48 | 54 | 68 | 74 | 101 |
| Total Income | 1652 | 1626 | 1602 | 1881 | 2177 | 2223 | 2323 | 3087 | 3119 | 2655 | 2970 | 3740 |
| Total Expenditure | 1543 | 1429 | 1433 | 1713 | 1995 | 1943 | 1893 | 2467 | 2685 | 2404 | 2607 | 3255 |
| Operating Profit | 109 | 197 | 169 | 168 | 181 | 280 | 430 | 620 | 434 | 251 | 362 | 485 |
| Interest | 40 | 30 | 36 | 52 | 56 | 53 | 42 | 40 | 55 | 89 | 100 | 142 |
| Depreciation | 35 | 36 | 42 | 51 | 54 | 65 | 59 | 63 | 75 | 89 | 100 | 136 |
| Exceptional Income / Expenses | 3 | -7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7 |
| Profit Before Tax | 38 | 124 | 91 | 64 | 72 | 163 | 329 | 517 | 304 | 72 | 163 | 200 |
| Provision for Tax | 11 | 28 | 5 | -0 | 11 | 49 | 92 | 120 | 60 | 10 | 30 | 46 |
| Profit After Tax | 28 | 96 | 86 | 64 | 61 | 113 | 237 | 397 | 244 | 62 | 133 | 157 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 28 | 96 | 86 | 64 | 61 | 113 | 237 | 397 | 244 | 62 | 133 | 157 |
| Adjusted Earnings Per Share | 9.5 | 33 | 29.4 | 22.1 | 21 | 38.9 | 86.9 | 145.5 | 92.9 | 23.7 | 50.8 | 59.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 12% | -2% | 6% | 6% |
| Operating Profit CAGR | 44% | -16% | 5% | 13% |
| PAT CAGR | 115% | -31% | 3% | 17% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -35% | 8% | 7% | 12% |
| ROE Average | 10% | 11% | 21% | 17% |
| ROCE Average | 10% | 12% | 18% | 14% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 381 | 456 | 573 | 620 | 680 | 741 | 854 | 1191 | 1298 | 1348 | 1466 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 239 | 223 | 349 | 405 | 432 | 355 | 338 | 480 | 547 | 680 | 1038 |
| Other Non-Current Liabilities | 57 | 79 | 122 | 103 | 99 | 119 | 163 | 224 | 263 | 321 | 352 |
| Total Current Liabilities | 403 | 384 | 501 | 635 | 657 | 690 | 766 | 859 | 1003 | 1163 | 1247 |
| Total Liabilities | 1079 | 1142 | 1544 | 1763 | 1869 | 1905 | 2120 | 2753 | 3110 | 3512 | 4103 |
| Fixed Assets | 595 | 647 | 961 | 994 | 984 | 1004 | 1005 | 989 | 1414 | 1578 | 1808 |
| Other Non-Current Assets | 80 | 126 | 71 | 108 | 142 | 115 | 121 | 391 | 367 | 532 | 738 |
| Total Current Assets | 404 | 368 | 513 | 660 | 742 | 781 | 992 | 1373 | 1329 | 1382 | 1558 |
| Total Assets | 1079 | 1142 | 1544 | 1763 | 1869 | 1905 | 2120 | 2753 | 3110 | 3512 | 4103 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 54 | 18 | 26 | 19 | 40 | 57 | 26 | 63 | 46 | 33 | 25 |
| Cash Flow from Operating Activities | 129 | 223 | 50 | 82 | 143 | 240 | 335 | 481 | 465 | 245 | 166 |
| Cash Flow from Investing Activities | -43 | -80 | -223 | -123 | -90 | -106 | -105 | -447 | -325 | -235 | -420 |
| Cash Flow from Financing Activities | -121 | -138 | 165 | 62 | -35 | -165 | -193 | -52 | -153 | -19 | 247 |
| Net Cash Inflow / Outflow | -35 | 6 | -7 | 21 | 17 | -31 | 37 | -18 | -13 | -8 | -6 |
| Closing Cash & Cash Equivalent | 18 | 25 | 19 | 40 | 57 | 26 | 63 | 46 | 33 | 25 | 19 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 9.49 | 33 | 29.4 | 22.1 | 20.96 | 38.9 | 86.92 | 145.52 | 92.95 | 23.69 | 50.81 |
| CEPS(Rs) | 21.33 | 45.24 | 43.84 | 39.66 | 39.39 | 61.21 | 108.65 | 168.74 | 121.5 | 57.78 | 88.79 |
| DPS(Rs) | 3.5 | 10 | 10 | 6 | 6 | 10 | 25 | 35 | 5 | 3 | 4 |
| Book NAV/Share(Rs) | 130.53 | 156.47 | 195.98 | 211.4 | 231.48 | 251.94 | 311.69 | 434.46 | 489.75 | 506.83 | 552.1 |
| Core EBITDA Margin(%) | 5.97 | 11.06 | 9.06 | 7.09 | 7.24 | 11.39 | 16.45 | 18.27 | 12.14 | 6.87 | 9.68 |
| EBIT Margin(%) | 4.49 | 8.92 | 7.49 | 6.2 | 5.73 | 9.4 | 15.55 | 17.79 | 11.47 | 6.06 | 8.84 |
| Pre Tax Margin(%) | 2.2 | 7.17 | 5.38 | 3.41 | 3.22 | 7.11 | 13.8 | 16.51 | 9.7 | 2.71 | 5.49 |
| PAT Margin (%) | 1.59 | 5.57 | 5.05 | 3.43 | 2.74 | 4.95 | 9.95 | 12.68 | 7.79 | 2.33 | 4.49 |
| Cash Profit Margin (%) | 3.57 | 7.63 | 7.54 | 6.16 | 5.16 | 7.79 | 12.43 | 14.7 | 10.18 | 5.68 | 7.84 |
| ROA(%) | 2.48 | 8.67 | 6.38 | 3.9 | 3.37 | 6.01 | 11.77 | 16.28 | 8.32 | 1.88 | 3.5 |
| ROE(%) | 7.47 | 23 | 16.69 | 10.85 | 9.46 | 16.09 | 29.91 | 39 | 19.76 | 4.75 | 9.6 |
| ROCE(%) | 8.6 | 17.63 | 12.25 | 8.94 | 8.8 | 14.26 | 23.56 | 30.79 | 17.16 | 7.17 | 10.2 |
| Receivable days | 27.28 | 25.27 | 30.12 | 34.48 | 32.89 | 32.04 | 29.24 | 23.83 | 24.43 | 31.53 | 35.27 |
| Inventory Days | 40.05 | 37.11 | 44.05 | 50.51 | 45.89 | 44.06 | 49.81 | 54.19 | 63.42 | 71.49 | 68.42 |
| Payable days | 39.4 | 38.79 | 34.66 | 26 | 25.19 | 28.12 | 30.87 | 32.26 | 35.96 | 42.29 | 37.29 |
| PER(x) | 5.42 | 5.88 | 8.45 | 7.45 | 6.17 | 3.57 | 4.76 | 7.94 | 6.33 | 21.08 | 12.14 |
| Price/Book(x) | 0.39 | 1.24 | 1.27 | 0.78 | 0.56 | 0.55 | 1.33 | 2.66 | 1.2 | 0.99 | 1.12 |
| Dividend Yield(%) | 4.54 | 3.44 | 2.68 | 2.43 | 3.09 | 7.19 | 4.03 | 2.02 | 0.85 | 0.6 | 0.65 |
| EV/Net Sales(x) | 0.37 | 0.59 | 0.83 | 0.66 | 0.51 | 0.51 | 0.79 | 1.28 | 0.78 | 0.87 | 1.02 |
| EV/Core EBITDA(x) | 5.62 | 4.86 | 7.8 | 7.27 | 6.08 | 4.04 | 4.22 | 6.29 | 5.5 | 8.97 | 8.14 |
| Net Sales Growth(%) | 12.15 | -1.59 | -2.08 | 16.36 | 16.79 | 2.18 | 3.71 | 32.96 | 0.89 | -15.59 | 11.89 |
| EBIT Growth(%) | 88.56 | 97.46 | -17.59 | -8.43 | 9.65 | 68.8 | 71.96 | 50.22 | -35.42 | -54.99 | 62.38 |
| PAT Growth(%) | 602.91 | 247.94 | -10.91 | -24.85 | -5.15 | 85.63 | 108.83 | 67.42 | -38.48 | -74.51 | 114.46 |
| EPS Growth(%) | 602.92 | 247.94 | -10.91 | -24.85 | -5.15 | 85.63 | 123.43 | 67.42 | -36.13 | -74.51 | 114.46 |
| Debt/Equity(x) | 1.29 | 0.93 | 1.09 | 1.28 | 1.2 | 1.07 | 0.9 | 0.68 | 0.69 | 0.74 | 0.94 |
| Current Ratio(x) | 1 | 0.96 | 1.02 | 1.04 | 1.13 | 1.13 | 1.29 | 1.6 | 1.33 | 1.19 | 1.25 |
| Quick Ratio(x) | 0.56 | 0.51 | 0.55 | 0.6 | 0.71 | 0.73 | 0.81 | 0.95 | 0.79 | 0.75 | 0.77 |
| Interest Cover(x) | 1.96 | 5.11 | 3.54 | 2.22 | 2.28 | 4.1 | 8.89 | 13.98 | 6.48 | 1.81 | 2.64 |
| Total Debt/Mcap(x) | 3.27 | 0.75 | 0.86 | 1.64 | 2.15 | 1.95 | 0.67 | 0.26 | 0.58 | 0.75 | 0.84 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 45.04 | 45.04 | 45.04 | 45.04 | 40.98 | 40.98 | 40.98 | 40.86 | 40.86 | 40.78 |
| FII | 3.45 | 3.19 | 3.24 | 2.57 | 3.99 | 3.12 | 3.49 | 3.24 | 2.68 | 2.13 |
| DII | 0.76 | 0.03 | 0.69 | 0.86 | 0.7 | 0.1 | 0.68 | 0.48 | 0.84 | 1.13 |
| Public | 50.76 | 51.74 | 51.04 | 51.54 | 54.33 | 55.8 | 54.85 | 55.42 | 55.62 | 55.96 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.18 | 1.18 | 1.18 | 1.18 | 1.08 | 1.08 | 1.08 | 1.07 | 1.07 | 1.07 |
| FII | 0.09 | 0.08 | 0.09 | 0.07 | 0.1 | 0.08 | 0.09 | 0.08 | 0.07 | 0.06 |
| DII | 0.02 | 0 | 0.02 | 0.02 | 0.02 | 0 | 0.02 | 0.01 | 0.02 | 0.03 |
| Public | 1.33 | 1.36 | 1.34 | 1.35 | 1.43 | 1.46 | 1.44 | 1.45 | 1.46 | 1.47 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +12% | -2% | +6% | +6% |
| Operating Profit CAGR | +44% | -16% | +5% | +13% |
| PAT CAGR | +115% | -31% | +3% | +17% |
| Share Price CAGR | -35% | +8% | +7% | +12% |
| ROE Average | +10% | +11% | +21% | +17% |
| ROCE Average | +10% | +12% | +18% | +14% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 45.04 | 45.04 | 45.04 | 45.04 | 40.98 | 40.98 | 40.98 | 40.86 | 40.86 | 40.78 |
| FII | 3.45 | 3.19 | 3.24 | 2.57 | 3.99 | 3.12 | 3.49 | 3.24 | 2.68 | 2.13 |
| DII | 0.76 | 0.03 | 0.69 | 0.86 | 0.7 | 0.1 | 0.68 | 0.48 | 0.84 | 1.13 |
| Public | 54.96 | 54.96 | 54.96 | 54.96 | 59.02 | 59.02 | 59.02 | 59.14 | 59.14 | 59.22 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.18 | 1.18 | 1.18 | 1.18 | 1.08 | 1.08 | 1.08 | 1.07 | 1.07 | 1.07 |
| FII | 0.09 | 0.08 | 0.09 | 0.07 | 0.1 | 0.08 | 0.09 | 0.08 | 0.07 | 0.06 |
| DII | 0.02 | 0 | 0.02 | 0.02 | 0.02 | 0 | 0.02 | 0.01 | 0.02 | 0.03 |
| Public | 1.44 | 1.44 | 1.44 | 1.44 | 1.55 | 1.55 | 1.55 | 1.55 | 1.55 | 1.55 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 | 2.62 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.